Moclobemide for anxiety disorders: a focus on moclobemide for panic disorder.
Int Clin Psychopharmacol
; 12 Suppl 6: S27-30, 1997 Oct.
Article
em En
| MEDLINE
| ID: mdl-9466172
ABSTRACT
Moclobemide is a reversible selective inhibitor of monoamine oxidase A. It has proven efficacy in a wide range of depressive disorders, including agitated anxious depression. In an international, multicentre, double-blind parallel-group study, the tolerability and efficacy of moclobemide were compared with that of the selective serotonin reuptake inhibitor fluoxetine. The target dose of moclobemide was 450 mg/day in the dose range of 300-600 mg/day, while the target dose for fluoxetine was 20 mg/day in the dose range of 10-30 mg/day. There were two consecutive studies. The first was an 8-week short-term study of acute adverse events, tolerability and efficacy. The efficacy data showed no significant difference between moclobemide and fluoxetine. Evaluation of the tolerability in a long-term study of up to 1 year is still in progress. A review of the moclobemide safety database for panic disorder with 624 patients showed a marginal increase in events with moclobemide compared with placebo for insomnia (11.2%), dizziness (4.5%) and dry mouth (3.7%), with rates for headaches and nausea lower for moclobemide than placebo. These data suggest moclobemide is a well tolerated and effective treatment for panic disorder.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Ansiedade
/
Benzamidas
/
Transtorno de Pânico
/
Inibidores da Monoaminoxidase
Tipo de estudo:
Clinical_trials
Limite:
Adult
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Int Clin Psychopharmacol
Assunto da revista:
PSICOFARMACOLOGIA
Ano de publicação:
1997
Tipo de documento:
Article
País de afiliação:
Austrália